secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0001828185-25-000018
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus Bio FY2024 net loss $61.1M; cash runway into 2027; VTP-1000 data Q3 2025
--------------------------------------------------------------------------------

- Net loss of $61.1M ($1.55 per share) vs $73.3M in 2023; goodwill impairment of $12.2M.
- Cash $112.4M at Dec 31, 2024, down from $142.1M; expected cash runway into 2027.
- Revenue $15.0M from Vaxzevria royalties (no future payments expected).
- Lead candidate VTP-1000 (celiac disease) Phase 1 AVALON trial; single ascending dose data expected Q3 2025.
- VTP-300 for CHB achieved 8 participants with HBsAg loss, 2 functional cures; Phase 2b data due Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000182818525000018/0001828185-25-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000182818525000018/brns-20250320.htm
  HTML page:      https://secwatch.observer/filing/0001828185-25-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer